专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009134079A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134079A2
公开(公告)日：2009-11-05
申请号：PCT/KR2009002261
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO , LEE YOUNG JOO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO
IPC分类号： A61K9/22
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Irbesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Valsartan-containing retard release compartment, (5) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Telmisartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (7) a release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and a Losartan-containing retarded release compartment, and (8) release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and an Irbesartan-containing retard release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含阿托伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含阿托伐他汀的早期释放隔室和厄贝沙坦的释放控制药物制剂（3）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含有奥美沙坦的缓释隔室，（4）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含缬沙坦的延迟释放隔室，（5）包含含阿托伐他汀的早期释放隔室和含替米沙坦的缓释隔室的释放控制药物制剂，（6）包含含阿托伐他汀的早期释放的释放控制药物制剂 COM （7）包含匹伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，和（8）包含匹伐他汀的释放控制药物制剂早泄室和含有厄贝沙坦的缓释隔室。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的具体组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出非常优异的治疗或预防疾病的效果。

2. 发明申请

WO2009134079A9 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134079A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002261
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO , LEE YOUNG JOO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44 , A61K47/00
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Irbesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Valsartan-containing retard release compartment, (5) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Telmisartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (7) a release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and a Losartan-containing retarded release compartment, and (8) release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and an Irbesartan-containing retard release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含阿托伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含阿托伐他汀的早期释放隔室和厄贝沙坦的释放控制药物制剂（3）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含有奥美沙坦的缓释隔室，（4）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含缬沙坦的延迟释放隔室，（5）包含含阿托伐他汀的早期释放隔室和含替米沙坦的缓释隔室的释放控制药物制剂，（6）包含含阿托伐他汀的早期释放的释放控制药物制剂 COM （7）包含匹伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，和（8）包含匹伐他汀的释放控制药物制剂早泄室和含有厄贝沙坦的缓释隔室。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的具体组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出非常优异的治疗或预防疾病的效果。

3. 发明申请

WO2009125987A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶钙通道阻断剂的缓释隔室和具有血管紧张素-2受体阻断剂的速释隔室的药物制剂。本发明提供了这样的药物制剂，其中二氢吡啶钙通道阻断剂和血管紧张素-2受体阻断剂分别包含在每个隔室中并且其释放受到控制。由于制剂的每个不同区室中所含的每种不同药物在不同时间释放，本发明的药物制剂使药物之间的拮抗作用和副作用最小化，并使药物的特定作用最大化。通过本发明的两种药物之间的特定组合的药物制剂与单独施用每种药物或简单联合施用药物相比，在治疗或预防疾病方面具有显着的良好效果。

4. 发明申请

WO2009125987A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶类钙通道阻滞剂的延长释放室和具有血管紧张素-2受体阻断剂的立即释放室的药物制剂。本发明提供了药物制剂，其中二氢吡啶类钙通道阻滞剂和血管紧张素-2受体阻断剂分别包含在每个隔室中，并且其释放被控制。由于制剂的每个不同隔室中包含的每种不同药物在不同的时间被释放，所以本发明的药物制剂使药物之间的拮抗作用和副作用最小化并使药物的具体效果最大化。根据本发明的两种药物之间的具体组合，通过与各药物的单次给药或药物的简单组合给药，治疗或预防疾病具有显着的效果。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式